Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPAACT 2021: Safety and Immunogenicity of RSV Vaccines in Children
NCT03916185Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2019
- Primary completion
- Jan 2024
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RSVt vaccine, RSV 6120/ΔNS2/1030s and RSV MEDI ΔM2-2 in respiratory syncytial virus infection (RSV), sponsored by National Institute of Allergy and Infectious Diseases. Started Jun 2019; status: terminated.
02
Drugs
RSVt vaccineRSV 6120/ΔNS2/1030sRSV MEDI ΔM2-2
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03916185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03916185.